An urgent health warning has been issued after 82 deaths in the UK were linked to weight-loss and diabetes drugs such as Ozempic and Mounjaro. The Medicines and Healthcare products Regulatory Agency (MHRA) reported at least 22 fatalities connected to weight-loss medication up to the end of January. A further 60 deaths were recorded for products used to treat Type 2 diabetes. Nearly 400 people have required hospital treatment since these products were rolled out.

The NHS warns patients to “never take an anti-obesity medicine if it has not been prescribed to you.”

Figures from the MHRA reveal that 18 deaths were linked to Mounjaro, which was recently approved for NHS use. A further 29 fatalities occurred in patients taking Ozempic, Rybelsus or Wegovy, which contain the active ingredient semaglutide. The highest death toll was associated with Saxenda and Victoza, with 35 reported fatalities. These medications are currently taken by an estimated half a million people across the UK.

The warning comes six months after a Scottish nurse became the first person in Britain whose death was directly linked to a weight-loss jab. Susan McGowan, 58, died at University Hospital Monklands in Airdrie on September 4 after suffering multiple organ failure, septic shock and pancreatitis. She had taken two low-dose injections of Mounjaro, also known as tirzepatide, which she purchased from an online pharmacy.

Reported side effects of these medications include nausea, vomiting and diarrhoea. Some doctors have warned of “life-threatening complications” such as seizures or bowel obstruction.

Currently, these drugs can be obtained from major chemists by completing an online form with weight and height details and submitting photographs. The Society for Acute Medicine has joined other experts in calling for stricter controls on how these weight-loss products are prescribed.

Dr. Alison Cave, MHRA chief safety officer, said, “The decision to start, continue or stop treatments should be made jointly by patients and their doctor, based on full consideration of benefits and risks.”

A spokesman for Lilly UK, which manufactures Mounjaro, stated that patient safety is their “top priority.” The company added, “Regulatory agencies conduct extensive independent assessments of the benefits and risks of every new medicine and Lilly is committed to continually monitoring, evaluating, and reporting safety data.”

The MHRA has emphasized that healthcare professionals must advise whether these medications are necessary for patients. Patients can currently access these drugs through major pharmacy chains by completing online forms and providing photographs. Medical organizations, including the Society for Acute Medicine, are now calling for tighter restrictions on how Ozempic, Mounjaro and other weight-loss products are prescribed.

Anyone experiencing side effects while taking these medications is advised to consult their doctor or healthcare professional.

Implications for the U.S. Market

While the warning was issued in the UK, the implications for the U.S. market are significant. Many of these drugs are also widely prescribed in the United States, and similar concerns about safety and efficacy have been raised by healthcare professionals. The U.S. Food and Drug Administration (FDA) has been monitoring these drugs closely, but the recent developments in the UK highlight the need for continued vigilance.

For instance, the FDA has received reports of similar side effects, including pancreatitis and bowel obstruction, in patients taking these medications. The agency has issued warnings and updated labeling for some of these drugs, but the latest data from the UK suggests that more stringent controls and monitoring may be necessary.

Case Study: The Rise of Online Pharmacies

The ease of accessing these medications through online pharmacies has raised concerns about patient safety. In the U.S., the rise of telemedicine and online pharmacies has made it easier for patients to obtain prescription drugs without a thorough medical evaluation. This trend has been accelerated by the COVID-19 pandemic, which has led to an increase in online consultations and prescriptions.

However, this convenience comes with risks. Patients may not receive the necessary medical oversight, and the potential for misuse or adverse reactions increases. The case of Susan McGowan in the UK serves as a stark reminder of the dangers of self-medication and the importance of proper medical supervision.

Counterarguments and Future Directions

Critics argue that the benefits of these medications outweigh the risks, especially for patients with severe obesity or Type 2 diabetes. They point to the significant improvements in health outcomes and quality of life that these drugs can provide. However, the recent data from the UK suggests that the risks may be higher than previously thought, and the need for stricter controls is clear.

Moving forward, there is a pressing need for more comprehensive research and monitoring. Healthcare providers, regulatory agencies, and pharmaceutical companies must work together to ensure that these medications are used safely and effectively. This includes developing better guidelines for prescribing, improving patient education, and enhancing post-market surveillance.